Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMTX705 in advanced solid tumors
NCT05547321Phase 1Recruiting
- Sponsor
- Oncomatryx
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Immunotoxins, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label trial of OMTX705 in solid tumor (advanced stage) (7 arms), sponsored by Oncomatryx. Primary endpoints: Safety evaluation of OMTX705 at 42 months, Maximum Tolerated Dose at 21 days and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
OMTX705
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05547321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547321.